Sugi Predict

Sugi Predict / Targets / STK16

STK16

Serine/threonine-protein kinase 16 · O75716 · STK16 on Sugi Atlas →

37,562 patent compounds predicted against STK16, 31,834 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL147331 SCHEMBL147331 0.91 2/20
SCHEMBL141930 SCHEMBL141930 0.90 2/20
SCHEMBL142206 SCHEMBL142206 0.85 2/20
SCHEMBL144842 SCHEMBL144842 0.80 2/20
SCHEMBL144192 SCHEMBL144192 0.75 2/20
SCHEMBL144525 SCHEMBL144525 0.71 2/20
SCHEMBL146263 SCHEMBL146263 0.71 2/20
SCHEMBL141676 SCHEMBL141676 0.69 2/20
SCHEMBL145500 SCHEMBL145500 0.69 2/20
SCHEMBL144281 SCHEMBL144281 0.68 2/20
SCHEMBL141372 SCHEMBL141372 0.68 2/20
SCHEMBL145902 SCHEMBL145902 0.67 2/20
SCHEMBL146743 SCHEMBL146743 0.67 2/20
SCHEMBL144785 SCHEMBL144785 0.67 2/20
SCHEMBL147096 SCHEMBL147096 0.63 2/20
SCHEMBL144209 SCHEMBL144209 0.62 2/20
SCHEMBL144321 SCHEMBL144321 0.61 2/20
SCHEMBL146728 SCHEMBL146728 0.61 2/20
SCHEMBL147975 SCHEMBL147975 0.60 2/20
SCHEMBL144930 SCHEMBL144930 0.60 2/20

Clinical trials — most relevant to STK16 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Signal TrAnsduction Pathway Activity Analysis in OVarian cancER PHASE2/PHASE3RECRUITING
Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations PHASE2COMPLETED
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) PHASE2COMPLETED
Metformin Plus/Minus Fasting Mimicking Diet to Target the Metabolic Vulnerabilities of LKB1-inactive Lung Adenocarcinoma PHASE2UNKNOWN
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours PHASE2ACTIVE_NOT_RECRUITING
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease PHASE2COMPLETED
Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation. PHASE2ACTIVE_NOT_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer PHASE2RECRUITING
Neoadjuvant Zoledronate and Atorvastatin in Triple Negative Breast Cancer PHASE2COMPLETED
Bempedoic Acid Therapy for Polycystic Kidney Disease PHASE2NOT_YET_RECRUITING
Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma PHASE2COMPLETED
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI PHASE2COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors PHASE1RECRUITING
A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion). PHASE1ACTIVE_NOT_RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON) PHASE1COMPLETED
A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. PHASE1ACTIVE_NOT_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Exercise in Type 1 Diabetes Mellitus nanCOMPLETED
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
New Genes in the Carcinogenesis of Colorectal Cancer nanUNKNOWN
NTRK 1,2,3 Rearrangements in Patients With Solid Tumors nanACTIVE_NOT_RECRUITING
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a STK16 binder may also engage these)

ProteinNameSimilarity
P57760 — 1.000 P57760 →
O88697 — 1.000 O88697 →
P59895 — 0.969 P59895 →
Q8RXG3 — 0.966 Q8RXG3 →
NEK6 Serine/threonine-protein kinase Nek6 0.965 landscape →
A2BD05 — 0.964 A2BD05 →
O09110 — 0.962 O09110 →
Q8WP15 — 0.962 Q8WP15 →
Q9ES74 — 0.962 Q9ES74 →
P70236 — 0.961 P70236 →
Q9U6D2 — 0.961 Q9U6D2 →
Q9ES70 — 0.961 Q9ES70 →
Q9DGE0 — 0.960 Q9DGE0 →
MAP2K3 Dual specificity mitogen-activated protein kinase kinase 3 0.960 landscape →
ULK3 Serine/threonine-protein kinase ULK3 0.960 landscape →
MAP2K6 Dual specificity mitogen-activated protein kinase kinase 6 0.960 landscape →
Q5E9X2 — 0.960 Q5E9X2 →
Q6PG34 — 0.960 Q6PG34 →
Q9WVS7 — 0.959 Q9WVS7 →
P21708 — 0.959 P21708 →
O80397 — 0.959 O80397 →
D3ZHP7 — 0.959 D3ZHP7 →
P28327 — 0.959 P28327 →
NEK7 Serine/threonine-protein kinase Nek7 0.959 landscape →
NPR1 Atrial natriuretic peptide receptor 1 0.959 landscape →
MAPK11 Mitogen-activated protein kinase 11 0.958 landscape →
Q9WUI1 — 0.958 Q9WUI1 →
Q3U3Q1 — 0.958 Q3U3Q1 →
Q63844 — 0.958 Q63844 →
MAPK3 Mitogen-activated protein kinase 3 0.958 landscape →